HB 70

For TennCare health benefit plan s renewed or issued on or after July 1, 2025, this bill requires the health insurance carrier to provide coverage and reimbursement for biomarker testing for preeclampsia if the conditions of this bill, as describe d below, are met. As used in this bill, a '' b iomarker test" means the analysis of a patient's tissue, blood, or other biospecimen for the presence of a biomarker using a method of analysis approved by the federal food and drug administration (FDA), includ ing single-analyte tests, multiplex panel tests, whole genome sequencing, protein expression, whole exome, and whole transcriptome . Under this bill, a pregnant woman may be screened for preeclampsia using biomarker testing when ordered by the pregnant wo man's attending physician. Additionally, the test must be conducted by the physician or other healthcare provider who is providing prenatal care for the pregnant woman according to nationally recognized clinical practice guidelines and consensus statemen t s. This bill authorizes the division of TennCare to promulgate rules to effectuate this bill and to submit to the federal centers for medicare and medicaid services (CMS) new waiver applications and amendments to existing waivers necessary to ensure fed eral financial participation for medicaid coverage pursuant to this bill."